US 12,433,861 B2
Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
Byoung Joo Gwag, Yongin-Si (KR); Chun San An, Suwon-si (KR); Jing Yu Jin, Suwon-Si (KR); Sung Ig Cho, Seoul (KR); Fangmeng Zhu, Hangzhou Zhejiang (CN); Xinliang Xu, Dongyang Zhejiang (CN); Weiqiang Zhan, Alpharetta, GA (US); Fuxin Liu, Hangzhou Zhejiang (CN); and Soon-Mi Won, Hwaseong-Si (KR)
Assigned to GNT Pharma Co., Ltd., Yongin-si (KR)
Filed by GNT Pharma Co., Ltd., Yongin-si (KR)
Filed on Aug. 21, 2023, as Appl. No. 18/235,986.
Application 18/235,986 is a division of application No. 17/197,736, filed on Mar. 10, 2021, granted, now 11,826,329.
Claims priority of provisional application 62/988,187, filed on Mar. 11, 2020.
Prior Publication US 2023/0390231 A1, Dec. 7, 2023
Int. Cl. A61K 31/196 (2006.01); A61K 38/48 (2006.01); A61K 45/06 (2006.01); A61P 7/02 (2006.01); A61P 9/10 (2006.01)
CPC A61K 31/196 (2013.01) [A61K 38/482 (2013.01); A61K 45/06 (2013.01); A61P 7/02 (2018.01); A61P 9/10 (2018.01)] 20 Claims
 
1. A method of preventing or reducing hemorrhagic transformation in an ischemic stroke patient receiving a recanalization therapy with a thrombolytic drug, endovascular thrombectomy (EVT), or endovascular thrombectomy with a thrombolytic therapy, comprising administering to the patient a composition comprising a compound of formula (I):

OG Complex Work Unit Chemistry
wherein
R1, R2, and R3, are, independently, hydrogen or halogen;
R4 is hydroxy, alkyl, alkoxy, halogen, alkanoyloxy, or nitro; and
R5 is carboxylic acid, carboxylic acid ester, carboxyamide, sulfonic acid, halogen, or nitro, or a pharmaceutically acceptable salt thereof.